|
|
|
|
Vol. 62, Issue 3, 566-577, September 2002
-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic
Acid (AMPA) Receptor Biophysics and Synaptic Responses
Department of Pharmacology (A.C.A., Y.-F.X., M.K.), Southern
Illinois University School of Medicine, Springfield, Illinois; and
Departments of Psychiatry (R.G., G.L.) and Chemistry (D.P., R.C.),
University of California, Irvine, California
Alkyl-substituted benzothiadiazides (BTDs) were tested for their
effects on
(R,S)-
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors. In excised patches, the 5'-ethyl derivative "D1" blocked the desensitization of AMPA
receptor currents during prolonged application of glutamate
(EC50, 36 µM), and it slowed deactivation of responses
elicited by 1-ms glutamate pulses greater than 10-fold.
[3H]Fluorowillardiine binding to rat synaptic membranes
was increased by D1 by a factor of 3.6 (EC50, 17 µM) with
a Hill coefficient near 2. In hippocampal slices, the compound
reversibly increased excitatory postsynaptic currents and field
excitatory postsynaptic potentials (EPSPs) with thresholds around 10 µM. The size of the alkyl substituent influenced both the potency and
nature of the drug effect on synaptic currents: 5'-methyl compounds had
a 2-fold greater effect on response amplitude than on response
duration, whereas 5'-ethyl compounds like D1 caused greater increases
in duration than amplitude. In tests with recombinantly expressed AMPA
receptor subunits, D1 preferred the glutamate receptor (GluR) subunit
GluR4 flip (0.64 µM) over GluR4 flop (5.3 µM); similar affinities
but with smaller flip-flop differences were obtained for GluR1 through
3. These results show that D1 and congeners are significantly more
potent than the parent compound IDRA-21 and that they differ in
two fundamental aspects from cyclothiazide, the most widely studied
BTD: 1) D1 markedly increases the agonist affinity of AMPA receptors
and 2) it has immediate and large effects on field EPSPs. The large
gain in potency conferred by alkyl substitution suggests that the 5'
substituent is in intimate contact with the receptor, with the size of
the substituent determining the way in which receptor kinetics is changed.
This article has been cited by other articles:
![]() |
H. Jourdi, X. Lu, T. Yanagihara, J. C. Lauterborn, X. Bi, C. M. Gall, and M. Baudry Prolonged Positive Modulation of {alpha}-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Induces Calpain-Mediated PSD-95/Dlg/ZO-1 Protein Degradation and AMPA Receptor Down-Regulation in Cultured Hippocampal Slices J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 16 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Suzuki, M. Kessler, K. Montgomery, and A. C. Arai Divergent Effects of the Purinoceptor Antagonists Suramin and Pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on {alpha}-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Mol. Pharmacol., December 1, 2004; 66(6): 1738 - 1747. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Leever, S. Clark, A. M. Weeks, and K. M. Partin Identification of a Site in GluR1 and GluR2 That Is Important for Modulation of Deactivation and Desensitization Mol. Pharmacol., July 1, 2003; 64(1): 5 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Arai, Y.-F. Xia, G. Rogers, G. Lynch, and M. Kessler Benzamide-Type AMPA Receptor Modulators Form Two Subfamilies with Distinct Modes of Action J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1075 - 1085. [Abstract] [Full Text] [PDF] |
||||